Alkermes Announces Positive Topline Results From Clinical Study of Two-Month Dosing Option of ARISTADA® for Treatment of Schizophrenia

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. DFTX
7. GOOGL
8. MU
9. HOOD
10. IBM

Go back to Alkermes Announces Positive Topline Results From Clinical Study of Two-Month Dosing Option of ARISTADA® for Treatment of Schizophrenia

Alkermes plc (ALKS) Tops Q4 EPS by 3c; Announces Positive Top-Line Data from ARISTADA PK Study

February 25, 2016 7:08 AM EST

Alkermes plc (NASDAQ: ALKS) reported Q4 EPS of ($0.15), $0.03 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $163.1 million versus the consensus estimate of $162.21 million.

The company also announced positive topline data from a randomized, open-label, pharmacokinetic (PK) study evaluating a two-month dosing interval of ARISTADA® (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia. Results from the study showed that the 1064 mg dose of ARISTADA achieved therapeutically relevant plasma concentrations of aripiprazole with a PK profile that... More